Quanterix Corporation

Quanterix Corporation is a life sciences company dedicated to transforming healthcare through ultra-sensitive biomarker detection. Its core business involves developing and commercializing digital immunoassay platforms for research and diagnostics. The company's mission is to change how healthcare is provided by enabling researchers to closely examine the continuum from health to disease, thereby advancing precision health. Quanterix is headquartered in Billerica, Massachusetts, USA.

The company's proprietary Simoa (Single Molecule Array) technology is central to its offerings, allowing for the detection and quantification of protein biomarkers at concentrations far below traditional immunoassay limits. Quanterix provides a range of instruments, including the HD-X, SR-X, and SP-X systems, along with various assay kits and consumables. Additionally, it operates a CLIA-certified Accelerator Laboratory, offering research services and custom testing. These products and services cater to market segments such as neurology, oncology, cardiology, inflammation, and infectious diseases, serving academic institutions, biopharmaceutical companies, and contract research organizations globally.

In January 2026, Everett Cunningham was appointed President and CEO, bringing extensive leadership experience to the company. Quanterix has been active in expanding its capabilities, notably acquiring Akoya Biosciences in 2025 to integrate multiplexed tissue imaging with its blood-based biomarker detection platforms. The company also submitted a 510(k) premarket notification to the FDA in January 2026 for a multi-analyte algorithmic blood test designed for Alzheimer's disease detection. Quanterix reported full-year 2025 revenue of $138.9 million and anticipates achieving cash-flow breakeven in the second half of 2026, reinforcing its position as a leader in advancing precision medicine through early disease detection.